Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicentric Non-randomized Phase II of Pembrolizumab in Combination With Etoposide-cisplatin-based Chemotherapy in First-line Small Cell Ovarian Carcinoma of Hypercalcemic Type

NCT04602377 is registered in ClinicalTrials.gov with ARCAGY/ GINECO GROUP as lead sponsor.

NCT NCT04602377
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04602377 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicentric Non-randomized Phase II of Pembrolizumab in Combination With Etoposide-cisplatin-based Chemotherapy in First-line Small Cell Ovarian Carcinoma of Hypercalcemic Type
Lead sponsor
ARCAGY/ GINECO GROUP
Phase
Phase 2
Overall status
Recruiting
Start date
August 4, 2021
Completion date
February 28, 2030
Enrollment
27 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

small cell ovarian carcinoma